Ruwanthi N. Gunawardane, Ph.D. - Publications

Cell biology

18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Gunawardane RN, Fordstrom P, Piper DE, Masterman S, Siu S, Liu D, Brown M, Lu M, Tang J, Zhang R, Cheng J, Gates A, Meininger D, Chan J, Carlson T, et al. Agonistic Human Antibodies Binding To Lecithin-Cholesterol Acyltransferase Modulate High Density Lipoprotein Metabolism. The Journal of Biological Chemistry. PMID 26644477 DOI: 10.1074/jbc.M115.672790  0.52
2015 Piper DE, Romanow WG, Gunawardane RN, Fordstrom P, Masterman S, Pan O, Thibault ST, Zhang R, Meininger D, Schwarz M, Wang Z, King C, Zhou M, Walker NP. The high resolution crystal structure of human LCAT. Journal of Lipid Research. PMID 26195816 DOI: 10.1194/jlr.M059873  0.52
2013 Gunawardane RN, Nepomuceno RR, Rooks AM, Hunt JP, Ricono JM, Belli B, Armstrong RC. Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells. Molecular Cancer Therapeutics. 12: 438-47. PMID 23412931 DOI: 10.1158/1535-7163.MCT-12-0305  0.52
2012 Liu G, Abraham S, Tran L, Vickers TD, Xu S, Hadd MJ, Quiambao S, Holladay MW, Hua H, Ford Pulido JM, Gunawardane RN, Davis MI, Eichelberger SR, Apuy JL, Gitnick D, et al. Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic index. Journal of Medicinal Chemistry. 55: 3250-60. PMID 22380736 DOI: 10.1021/jm201702g  0.52
2012 James J, Ruggeri B, Armstrong RC, Rowbottom MW, Jones-Bolin S, Gunawardane RN, Dobrzanski P, Gardner MF, Zhao H, Cramer MD, Hunter K, Nepomuceno RR, Cheng M, Gitnick D, Yazdanian M, et al. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. Molecular Cancer Therapeutics. 11: 930-41. PMID 22319199 DOI: 10.1158/1535-7163.MCT-11-0645  0.52
2012 Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L, Struss B, Gibney M, Armstrong RC, Gunawardane RN, Nepomuceno RR, et al. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. Journal of Medicinal Chemistry. 55: 1082-105. PMID 22168626 DOI: 10.1021/jm2009925  0.52
2011 Holladay MW, Campbell BT, Rowbottom MW, Chao Q, Sprankle KG, Lai AG, Abraham S, Setti E, Faraoni R, Tran L, Armstrong RC, Gunawardane RN, Gardner MF, Cramer MD, Gitnick D, et al. 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors. Bioorganic & Medicinal Chemistry Letters. 21: 5342-6. PMID 21807507 DOI: 10.1016/j.bmcl.2011.07.019  0.52
2010 Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, et al. MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proceedings of the National Academy of Sciences of the United States of America. 107: 3698-703. PMID 20133671 DOI: 10.1073/pnas.0914203107  0.52
2009 Chao Q, Sprankle KG, Grotzfeld RM, Lai AG, Carter TA, Velasco AM, Gunawardane RN, Cramer MD, Gardner MF, James J, Zarrinkar PP, Patel HK, Bhagwat SS. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. Journal of Medicinal Chemistry. 52: 7808-16. PMID 19754199 DOI: 10.1021/jm9007533  0.52
2009 Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 114: 2984-92. PMID 19654408 DOI: 10.1182/blood-2009-05-222034  0.52
2006 Witt AE, Hines LM, Collins NL, Hu Y, Gunawardane RN, Moreira D, Raphael J, Jepson D, Koundinya M, Rolfs A, Taron B, Isakoff SJ, Brugge JS, LaBaer J. Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. Journal of Proteome Research. 5: 599-610. PMID 16512675 DOI: 10.1021/pr050395r  0.52
2005 Gunawardane RN, Sgroi DC, Wrobel CN, Koh E, Daley GQ, Brugge JS. Novel role for PDEF in epithelial cell migration and invasion. Cancer Research. 65: 11572-80. PMID 16357167 DOI: 10.1158/0008-5472.CAN-05-1196  0.52
2003 Gunawardane RN, Martin OC, Zheng Y. Characterization of a new gammaTuRC subunit with WD repeats. Molecular Biology of the Cell. 14: 1017-26. PMID 12631720 DOI: 10.1091/mbc.E02-01-0034  0.52
2001 Gunawardane RN, Zheng Y, Oegema K, Wiese C. Purification and reconstitution of Drosophila gamma-tubulin complexes. Methods in Cell Biology. 67: 1-25. PMID 11550462  0.52
2001 Gunawardane RN, Zheng Y, Oegema K, Wiese C. Purification and reconstitution of Drosophila γ-tubulin complexes Methods in Cell Biology. 1-25.  0.52
2000 Gunawardane RN, Martin OC, Cao K, Zhang L, Dej K, Iwamatsu A, Zheng Y. Characterization and reconstitution of Drosophila gamma-tubulin ring complex subunits. The Journal of Cell Biology. 151: 1513-24. PMID 11134079 DOI: 10.1083/jcb.151.7.1513  0.52
2000 Gunawardane RN, Lizarraga SB, Wiese C, Wilde A, Zheng Y. gamma-Tubulin complexes and their role in microtubule nucleation. Current Topics in Developmental Biology. 49: 55-73. PMID 11005014  0.52
1998 Martin OC, Gunawardane RN, Iwamatsu A, Zheng Y. Xgrip109: a gamma tubulin-associated protein with an essential role in gamma tubulin ring complex (gammaTuRC) assembly and centrosome function. The Journal of Cell Biology. 141: 675-87. PMID 9566968 DOI: 10.1083/jcb.141.3.675  0.52
Show low-probability matches.